PSC
DFTX

Patient Square Capital’s Definium Therapeutics DFTX Stock Holding History

Patient Square Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-331,000
Closed -$6.26M – 31
2026
Q1 		$6.26M Buy
+331,000
New +$5.62M 1.11% 23

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Patient Square Capital's DFTX Position: Q2 2026 in Review

Patient Square Capital sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 331,000 shares — an estimated $6.26M sold.

Patient Square Capital first reported a position in DFTX in Q1 2026 and held it in 1 quarter. The position peaked at $6.26M in Q1 2026. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Patient Square Capital reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Patient Square Capital sold 331,000 Definium Therapeutics shares in Q2 2026, an estimated $6.26M.
  • Patient Square Capital first reported a position in Definium Therapeutics in Q1 2026 and held it in 1 quarter.
  • Patient Square Capital's Definium Therapeutics position peaked at $6.26M in Q1 2026.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.